Cervical cancer deaths fell to zero among women aged 20-24 in England between 2020 and 2024 [1].
The findings suggest that the human papillomavirus (HPV) vaccination programme is successfully eliminating a leading cause of cancer in young women. This shift represents a significant public health milestone in the effort to eradicate cervical cancer through preventative medicine.
Researchers, including Peter Sasieni of Queen Mary University of London, analyzed national health data to determine the impact of the vaccine rollout [1]. The study found that zero deaths were recorded for the 20-24 age group during the four-year window [1]. Other reports indicate that for those vaccinated at ages 12-13, there is a risk close to zero of dying from the disease before age 30 [2].
The decline is attributed to the widespread administration of the HPV vaccine, which prevents the infections that cause most cervical cancers [2]. The data indicates that approximately 200 lives have been saved in England due to the vaccination efforts [3].
While some data suggests an absolute zero for the 20-24 age bracket, other analyses describe the risk as near-zero for those under 30 [2]. This distinction reflects the high efficacy of the vaccine rather than a total elimination of all risk factors.
"The results are stunning. It’s an awful thing when somebody dies very young from cervical cancer," Sasieni said [1].
“Cervical cancer deaths fell to zero among women aged 20-24 in England between 2020 and 2024.”
The elimination of cervical cancer deaths in this specific age cohort demonstrates the viability of vaccination as a primary prevention tool. If these trends continue and vaccination rates remain high, the UK could serve as a global model for the complete eradication of cervical cancer, shifting the medical focus from treatment and screening to total prevention.
